P2RY12 and anemia (phenotype): For patients who initiated prasugrel or ticagrelor, having an ARC-HBR major bleeding risk factor was associated with future deescalation; however, most individual bleeding risk factors showed no association except for anticoagulant use and anemia, suggesting that assessment of bleeding risk is more prominent in initial P2Y12 inhibitor selection vs deescalation.